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 Introduction 
 Nearly 50% of all deaths in Germany and other indus-
trial countries are related to cardiovascular diseases 
(CVD)  [1] . Most cardiovascular diseases are caused by 
atherosclerosis, which itself depends upon a multifacto-
rial process, with hypertension, smoking, obesity, and el-
evated serum low-density lipoprotein concentrations as 
important associated risk factors  [2] . Although it is not 
yet known whether an elevated homocysteine concentra-
tion is a causative factor in the development of athero-
sclerosis, some authors consider hyperhomocysteinemia 
to be an important and independent risk factor for car-
diovascular diseases  [3–6] .  To date, no standardized def-
inition of hyperhomocysteinemia exists  [7, 8] , but experts 
discuss levels of  ! 10   mol/l or even lower as being desir-
able in CVD prevention  [9] . Another important risk fac-
tor for coronary heart disease (CHD) are increased 
lipoprotein(a) (Lp(a)) concentrations, which are associ-
ated with an approximately 2-fold risk increase for CHD 
 [10–15] . Lp(a) concentrations are mainly genetically de-
termined. However, high therapeutic doses of niacin and 
hormone replacement therapy are known to have lower-
ing effects on Lp(a)  [14, 16] . 
 Key Words 
 Vegan   Cholesterol   Homocysteine   Lipoprotein(a)   
Cardiovascular risk 
 Abstract 
 Background/Aim: Evaluation of cardiovascular risk pro-
fi le in 154 German vegans.  Methods: Cross-sectional 
study, Germany. Study instruments: 2 FFQ, 2 question-
naires, analyses of fasting venous blood samples.  Re-
sults: The total study population had a low BMI (mean: 
22.3 kg/m2), a moderate blood pressure (mean: 
120/75 mm Hg), an extremely low consumption of alco-
hol (mean: 0.77 g/day) and 96.8% were nonsmokers. 
Moderate physical activity (PAL) was reported by
nearly 50%, whereas 22.7% declared to have a high
PAL ( 1 3 h/week). Median triacylglycerol (TG) was
0.81 mmol/l, total cholesterol (TC) was 4.33 mmol/l,
HDL was 1.34 mmol/l. The mean TC/HDL-ratio was 3.3. 
Lipo protein(a) (Lp(a)) was 8.13 mg/dl, concentrations of 
 1 30 mg/dl were prevalent in 25% of the participants.
In general, status of folate and pyridoxine were suffi -
cient, while 49.7% showed cobalamin concentrations 
 ! 150 pmol/l. Plasma homocysteine levels were slightly 
elevated (median: 12.5   mol/l). Cobalamin concentra-
tion and duration of vegan nutrition were the main de-
terminants of homocysteine in the total study popula-
tion.  Conclusion:  Although TC and LDL concentrations 
were favorable, low HDL and elevated homocysteine 
and Lp(a) concentrations were unfavorable. Overall, 
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 A broad spectrum of epidemiological data shows that 
vegetarians have lower CVD related morbidity and mor-
tality  [17,18] . While a lacto-ovo vegetarian diet can be 
recommended in this context, data on the overall CVD 
risk proﬁ le situation of vegans are limited. 
 The present study aimed at evaluating the cardiovas-
cular risk proﬁ le and related dietary and life-style factors 
in vegans. Participants were classiﬁ ed into strict and 
moderate vegans in order to investigate whether even a 
very small amount of ingested food of animal origin may 
have an impact on risk proﬁ le. 
 Methods 
 The German Vegan Study (GVS) was designed as a cross-sec-
tional study. Advertisements for subjects were placed in eight Ger-
man magazines. The GVS was conducted in accordance with the 
Helsinki Declaration of 1964 as revised 1983 and 1996. Since there 
was no intervention, the Ethics Commission of Lower Saxony con-
ﬁ rmed that ethical approval was not required. All subjects partici-
pated voluntarily and gave written consent prior to study begin. In-
clusion criteria were deﬁ ned as: vegan nutrition for one year prior to 
the beginning of the study, a minimum age of 18 years, no pregnan-
cy or childbirth during the last 12 months. Exclusion criteria were 
deﬁ ned as: Severe illness during the last 12 months (such as malig-
nant or cardiovascular diseases, renal failure and severe diseases of 
the gastrointestinal tract), diagnosed blood coagulation disorder, in-
take of inhibitors of blood coagulation, misuse of alcohol and/or 
drugs, participation in another study during the last month. 
 As previously described  [19] , participants were classiﬁ ed as veg-
an when adhering to either a strict vegan diet (SV) or a moderate 
vegan diet (MV), i.e. a maximum of 5% of the ingested energy was 
derived from eggs, milk and/or dairy products. On the one hand, 
the ingested amounts of eggs (0.88  8 3.31 g/day), milk and dairy 
products (7.95  8 10.1 g/day) in the moderate vegan subgroup was 
so low that it seemed not to be appropriate to name them restricted 
lacto-ovo-vegetarians. On the other hand, although all persons re-
ported to be vegans, some persons included food of animal origin 
in their diet. And the consumption of eggs, milk and dairy products 
makes it difﬁ cult – if not impossible at all – to name those persons 
(strict) vegans. Therefore, we decided to name them moderate veg-
ans rather than restricted lacto-ovo-vegetarians or strict vegans. 
 Each GVS participant was asked to complete two 9-day esti-
mated food frequency questionnaires (FFQ). The FFQ used was a 
slight modiﬁ cation (complemented for vegan foods, foods of ani-
mal origin (except eggs, butter, milk and dairy products) were ex-
cluded) of the validated FFQ used in the Giessen Raw Food Study 
 [20] . Altogether, the GVS-FFQ contained 199 vegan foods (incl. 18 
beverages) and 7 non vegan foods (i.e. eggs, milk, and other dairy 
products). In the FFQ common household measures and their 
equivalents in grams or milliliters were given for each food item. 
In some cases, portion sizes were made clear with photos or com-
ments (i.e. 9 walnut-size strawberries weighing 150 g, 1 orange with 
a size of a tennis ball equals 250 g). In addition, participants were 
asked for copies of recipes of home made vegan dishes. In order to 
minimize seasonal differences, one FFQ was sent in autumn, the 
other in spring. Members of the GVS team developed software 
(Paradox and Access database) on the basis of the German Nutri-
ent Data Base (BLS II.2, Bundesinstitut für gesundheitlichen 
Verbraucher schutz und Veterinärmedizin Berlin, Germany) to cal-
culate the concentrations of ingested nutrients. 
 A short pre-questionnaire was used to collect information on 
duration of vegan diet, kind of diet before adopting the vegan diet, 
inclusion of eggs, milk and other dairy products in the diet. Fur-
thermore the existence of inclusion and exclusion criteria was au-
dited. The main questionnaire contained questions regarding an-
thropometric, socioeconomic and health oriented data  [19] . 
 All subjects were screened for health status by a general practi-
tioner, who was a member of the GVS team, during time of blood 
collection. Standardization of screening was guaranteed by using a 
structured questionnaire that contained questions regarding major 
diseases (e.g. cancer, cardiovascular diseases, allergies), complica-
tions such as gastrointestinal problems as well as medication. Body 
weight was measured using a calibrated scale; body height, waist 
and hip circumference were surveyed via a tape measure. Body 
mass index (BMI) and waist-to-hip ratio (WHR) were computed 
using standard formulas. Pulse and blood pressure were recorded 
by a calibrated digital blood pressure meter. 
 A fasting venous blood sample was taken for the measurement 
of lipid parameters. Triacylglycerol concentrations were measured 
using an  enzymatic colorimetric test (GPO-PAP, Boehringer, Ger-
many). Total cholesterol was also assessed by an enzymatic colori-
metric test (CHOD-PAP, Boehringer), while LDL concentrations 
were measured by precipitation with polyvinylsulfate (Boehringer) 
and HDL by precipitation with phosphotungstic acid (Boehringer). 
Kinetic nephelometry was used to measure Lp(a) (Beckman, Ger-
many). An automated chemiluminescence system (ACS:180, Ciba 
Corning, Germany) was used to measure plasma cobalamin and 
red blood cell (RBC) folate concentrations  [21–23] . Plasma homo-
cysteine concentrations were measured using HPLC (Immunodi-
agnostic AG, Germany)  [24] . Pyridoxine status was analyzed by 
measuring the erythrocyte aspartic acid aminotransferase (EAST) 
activity after stimulation (EPOS Analyzer 5060, Eppendorf/Ham-
burg, Germany)  [25] . 
 The following cut-off points were used to deﬁ ne abnormal (ele-
vated or decreased) blood concentrations: TG  1 4.5 mmol/l, TC  1 5.2 
mmol/l, LDL  1 3.5 mmol/l, HDL  ! 0.9 mmol/l, TC/HDL  1 5, Lp(a) 
 1 30 mg/dl, homocysteine  1 10   mol/l ( 1 15   mol/l), cobalamin  ! 250 
pmol/l ( ! 150 pmol/l), folate 6.8 nmol/l, and alpha-EAST  ! 1.85. 
 A statistical analysis program (SPSS 12.0, Chicago, Ill., USA) 
was used to analyze the data. The results are shown as mean  8 SD 
and median plus 5th to 95th percentiles, respectively. The follow-
ing two-tailed tests at the 5% level of signiﬁ cance were used to 
evaluate the study: In case of skewness, the Mann-Whitney U test 
was used in case of two independent samples (SV and MV). Given 
normal distribution, the independent sample t test was used. Nor-
mal distribution of data was checked visually and by using the Kol-
mogorov-Smirnov test. Dealing with nominal data, the    2  test was 
employed to evaluate statistically signiﬁ cant differences. Correla-
tion analysis was done to reveal statistically signiﬁ cant associations 
between biochemical factors and dietary components. In case of 
skewness, the Spearman correlation coefﬁ cient was used, in case of 
normal distribution, Pearson’s correlation coefﬁ cient was used. 
Predictors of homocysteine were evaluated by stepwise multiple 
linear regression. A general linear model revealed signiﬁ cant pre-
dictors of plasma cobalamin concentration. 
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 Results 
 Altogether 154 subjects (98 SV and 56 MV) partici-
pated in all parts of the study (pre- and main question-
naire, two 9-day food-frequency questionnaires, and 
blood sampling) and fulﬁ lled all the study criteria and did 
not fulﬁ l any of the exclusion criteria.  Table 1 shows that 
strict and moderate vegans did not differ in anthropomet-
ric characteristics and life-style factors. The proportion 
of females was higher in the moderate vegan subgroup 
than in the strict vegan subgroup, but this difference 
missed statistical signiﬁ cance. As indicated in  table 2 , the 
subgroups differed signiﬁ cantly regarding energy intake, 
protein intake, energy derived from poly unsaturated fat-
Table 1. Anthropometric data and life-style factors of strict and moderate  vegans (mean 8 SD)
Strict vegans
(n = 98)
Moderate vegans
(n = 56)
p
Gender distribution, % (females:males) 51.0:49.0 66.1:33.9 0.070c
Age, years 43.4815.4 45.7814.2 0.358b
BMI, kg/m2 21.382.73 21.382.20 0.861b
WHR 0.8280.07 0.8180.08 0.244b
Systolic blood pressure, mm Hg 122819.6 117815.5 0.130b
Diastolic blood pressure, mm Hg 74.6811.1 75.989.58 0.802a
Pulse rate, beats per min 70.5810.9 68.788.83 0.316b
Physical activity
Low 25.5% 17.9% 0.546c
Middle 48.0% 51.8%
High 26.5% 30.4%
Duration of vegan nutrition, years 7.7086.40 5.0684.03 0.058a
Smokers, % 3.06 3.57 0.864c
a Mann-Whitney U test; b t test for unpaired samples; c ² test.
Table 2. Dietary intakes (total energy intake, relation of macronutrients, fatty acids, ﬁ ber and alcohol intake) of 
strict and moderate vegans (mean 8 SD)
Strict vegans
(n = 98)
Moderate vegans
(n = 56)
p
Energy intake, MJ/day 8.5982.97 7.6082.28 <0.033b
Carbohydrates, % of energy 56.487.74 58.686.94 0.146b
Protein, % of energy 11.982.11 11.081.90 0.013b
Fat, % of energy 30.388.22 28.887.02 0.255b
Saturated fatty acids, % of energy 5.9181.66 6.1681.84 0.377b
Monounsaturated fatty acids (MUFA), % of energy 12.585.50 12.384.79 0.817a
Polyunsaturated fatty acids (PUFA), % of energy 9.0683.48 7.8482.78 0.026b
n–6 fatty acids, g/day 19.2810.4 14.487.24 0.003a
n–3 fatty acids, g/day 1.9881.16 1.9481.13 0.791a
n–6:n–3 10.1:1 7.92:1 <0.001b
Alimentary cobalamin intake, g/day
(enriched/natural foods)
0.8181.74
(median: 0.29)
0.4680.81
(median: 0.23)
0.163a
Cholesterol, mg/day 18.0828.2 27.8823.7 <0.001a
Fiber, g/day 58.6822.2 53.5814.9 0.125b
Alcohol consumption, g/day 0.6683.15 0.9783.13 0.084a
a Mann-Whitney U test; b t test for unpaired samples.
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ty acids (PUFA), intake of n–6 fatty acids, relation of 
n–6 to n–3 fatty acids, and cholesterol intake: energy, 
protein, n–6 fatty acid intake and energy from PUFA 
were signiﬁ cantly higher in the SV study population, 
while cholesterol intake was signiﬁ cantly higher in the 
MV study population. As shown in  table 3 , median tria-
cylglycerol, total cholesterol, LDL, HDL, and Lp(a) se-
rum concentrations as well as the ratio of TC to HDL did 
not reach dimensions that are associated with an in-
creased CHD risk (TG  1 4.5 mmol/l, TC  1 5.2 mmol/l, 
LDL  1 3.5 mmol/l, HDL  ! 0.9 mmol/l, TC/HDL  1 5, Lp(a) 
 1 30 mg/dl)  [26] . Only total cholesterol differed statisti-
cally signiﬁ cantly between the subgroups, a higher me-
dian concentration was found in the MV subgroup. In the 
total study population the ratio of total cholesterol to 
HDL was 3.3 (2.20/5.47). Of the SV 9.3% and 5.4% of 
the MV showed a TC/HDL ratio  1 5. Plasma homocyste-
ine concentrations and status of related vitamins are 
shown in  table 4 . A general linear model (p = 0.002; R 2  = 
0.119) revealed dietary subgroup (beta = 0.043, p = 0.012), 
gender (beta = 0.027, p = 0.049) as signiﬁ cant predictors 
of plasma cobalamin concentration, while duration of 
vegan diet (beta = 0.011, p = 0.207) and cobalamin intake 
(beta = 0.008, p = 0.285) increased the fraction of ex-
plained variance marginally. In general, status of folate 
and pyridoxine was sufﬁ cient, while 58.3% of SV and 
34.5% of MV (p = 0.005) were cobalamin deﬁ cient (i.e. 
cobalamin  ! 150 pmol/l). Using a higher cut-off point of 
250 pmol/l 86.5% of SV and 69.1% of MV (p = 0.010), 
respectively, were considered as cobalamin deﬁ cient. 
When the dietary subgroups were differentiated accord-
ing to duration of vegan diet ( ! 5 years, 5 to  ! 10 years, 
 1 10 years) no clear association between the prevalence of 
cobalamin deﬁ ciency and the duration of vegan diet was 
seen: Persons in the middle time category were less af-
fected by cobalamin deﬁ ciency than in the other catego-
Strict vegans
(n = 98)
Moderate vegans
(n = 56)
p
Triacylglycerol, mmol/l 0.81 (0.40/1.67) 0.81 (0.46/2.67) 0.724a
Total cholesterol, mmol/l 4.31 (2.82/6.07) 4.44 (3.20/7.21) 0.044b
LDL, mmol/l 2.41 (1.27/3.97) 2.53 (1.48/5.14) 0.108b
HDL, mmol/l 1.31 (0.81/1.86) 1.40 (0.86/2.05) 0.070b
Total cholesterol/HDL 3.27 (2.14/5.80) 3.38 (2.0/5.19) 0.759a
Lipoprotein(a), mg/dl 9.40 (2.00/114) 6.73 (2.00/92.0) 0.110a
a Mann-Whitney U test; b t test for unpaired samples.
Table 3. Serum lipid proﬁ le of strict and 
moderate vegans (median, 5th to 95th 
 percentile)
Strict vegans
(n = 98)
Moderate vegans
(n = 56)
p
Plasma homocysteine, mol/l 13.3 (5.97/82.0) 11.1 (3.60/25.7) <0.004a
% with homocysteine >10 mol/l 71.1 57.1
Hcys <10 mol/l + duration of vegan diet
<5 years 65.5 50
5–<10 years 77.3 66.7
>10 years 80 100
Serum cobalamin, pmol/l 130 (72.1/294) 187 (93.6/748) <0.001a
% with cobalamin <250 pmol/l 86.5 69.1
Cob. <250 pmol/l + duration of vegan diet
<5 years 85.2 73.7
5–<10 years 77.3 57.1
>10 years 100 66.7
RBC folate, mmol/l 33.0 (18.1/46.5) 35.8 (17.8/45.3) <0.644b
Alpha-EAST 1.60 (1.30/2.00) 1.60 (1.26/2.00) <0.375a
a Mann-Whitney U test; b t test for unpaired samples.
Table 4. Plasma homocysteine and 
related vitamin status (median, 5th to 
95th  percentile)
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ries. However, in all time categories more SV than MV 
showed cobalamin concentrations  ! 250 pmol/l. Elevated 
homocysteine concentrations (i.e. homocysteine  1 10 
  mol/l) were present in 71.1% of SV and 57.1% of MV. 
The combination of elevated homocysteine ( 1 10   mol/l) 
and low cobalamin concentration ( ! 250 pmol/l) was 
found in 61.6% of the study population (SV: 67.7%, MV: 
50.9%; p = 0.041). When the dietary subgroups were dif-
ferentiated according to duration of vegan diet ( ! 5 years, 
5 to  ! 10 years,  6 10 years) prevalence of elevated homo-
cysteine concentrations increased with proceeding dura-
tion of vegan diet. 
 To analyze the relationship between homocysteine 
and inﬂ uencing variables a stepwise multiple linear re-
gression was carried out. In both, strict and moderate 
vegans, time of adhering to the vegan diet and cobalamin 
concentrations were predictors of homocysteine concen-
trations ( table 5 ). 
 Discussion 
 Known risk factors such as hypertension, elevated cho-
lesterol, smoking, and/or elevated plasma triacylglycerol 
contribute to 50% of CHD. Therefore, there must be oth-
er factors that are associated with the development of 
CHD  [27] . Two of these other factors may be elevated 
plasma homocysteine and Lp(a) concentrations, which 
have been shown to be associated with an increased risk 
of cardiovascular diseases  [14, 28] . Epidemiological data 
show that vegetarians and vegans are at relatively low risk 
for CVD  [17, 18] when considering conventional risk fac-
tors (e.g. total cholesterol, LDL, BMI, smoking, and alco-
hol consumption), but knowledge about Lp(a) and homo-
cysteine levels in vegans is still limited. For this reason 
the present study aimed at evaluating conventional CVD 
risk factors, homocysteine and Lp(a) concentrations in a 
vegan study population, which was divided into strict and 
moderate vegans. Focusing on life-style factors such as 
smoking, alcohol consumption, and physical activity it is 
obvious that the GVS study population was extremely 
health conscious. Only 3% of the study population smoked 
and nearly 40% of the study population consumed no al-
cohol at all. This may partly be due to the fact that over-
all 35% of the study population were Seventh-day Adven-
tists, who are especially health conscious  [29,30] . Our 
ﬁ ndings bear analogy to ﬁ ndings from other studies that 
report a comparatively high health consciousness in co-
horts with vegetarian life-styles  [31–34] . 
 Low mean BMI and WHR reﬂ ect low mean energy in-
take in the study population. The distribution of main nu-
trients to total energy intake meets the current recommen-
dations of nutrition societies  [35] . Carbohydrates were the 
main nutrients with an energy contribution of nearly 60%, 
whereas fats contributed to energy supply with nearly 30% 
of total energy intake. In regard to the fatty acid composi-
tion, the dietary pattern of the GVS study population ful-
ﬁ lled current recommendations of the NCEP (National 
Cholesterol Education Programme)  [36] and the Interna-
tional Task Force for the Prevention of Coronary Heart 
Disease  [26] . But relation of n–6:n–3 fatty acid intake was 
lower than the recommended relation for vegetarian and 
vegan populations of 2:  1 to 4:  1  [37] . Mean ﬁ bre intake was 
nearly 60 g/day and was nearly twice the current recom-
mendation to ingest 30 g/day  [35] . The high ﬁ bre intake is 
the consequence of the high fruit and vegetable intake of 
the study population (1,458  8 673 g/day). Alimentary co-
balamin intake was higher in strict vegans than in moder-
ate vegans due to the higher use of enriched foods in the 
SV subgroup. There might be an overestimation of the in-
Table 5. Multiple regression of homocysteine (log)
Standardized regression coefﬁ cients
total study population
(n = 154)
strict vegans
(n = 98)
moderate vegans
(n = 56)
beta p beta p beta p
Duration of vegan nutrition, years –0.428 <0.001 0.447 <0.001 0.301 <0.004
Serum cobalamin, pmol/l –0.451 <0.001 –0.386 <0.001 –0.600 <0.001
Adjusted R² 0.443 0.396 0.470
No signiﬁ cant relationship to gender, age, RBC folate concentrations and alpha-EAST activity coefﬁ cient 
(pyridoxine status), dietary folate, pyridoxine and cobalamin.
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gested amount of vitamin B 12  in the SV subgroup due to 
varying cobalamin contents of enriched foods and due to 
the insecurity of the bioactivity of the cobalamin com-
pounds that were used for enrichment. 
 The present study shows that vegans have a low risk 
lipid proﬁ le. This is especially obvious for LDL, triacylg-
lycerol and the TC/HDL ratio. Only 7.2% of the total 
study population showed a TC/HDL ratio  1 5, which is 
considered as a risk factor for CHD  [26] . However, HDL 
was low while Lp(a) and homocysteine are elevated in our 
study population. Our ﬁ ndings conﬁ rm data from previ-
ous studies with vegetarian  [38–40] and vegan cohorts  [4, 
39, 40] which show that a plant-based diet is related to a 
favourable lipid proﬁ le on the one hand, and that homo-
cysteine is more likely to be elevated in strict vegetarians 
(vegans) on the other hand. Elevated homocysteine con-
centrations may result from genetic defects  [41] , from 
deﬁ ciencies of cobalamin, folate, and/or pyridoxine. 
Thus, the adequate intake of these vitamins can optimize 
the homocysteine concentration  [27] . In omnivores hy-
perhomocysteinemia is mostly due to a low intake of fo-
late or pyridoxine. In persons with high folic acid intakes 
 [42] as well as in vegetarians and especially in vegans hy-
perhomocysteinemia is rather the consequence of cobala-
min deﬁ ciency  [39,43] . We also did not ﬁ nd correlations 
for RBC folate (r s  = 0.033; p  = 0.689) and pyridoxine
(r s = –0.08; p = 0.342) status with homocysteine, but for 
 cobalamin and homocysteine (r s  = –0.684; p  ! 0.001). 
Gerhard and Duell  [9] recommend concentrations of
 ! 10   mol/l in CHD prevention. Homocysteine concen-
trations above this cut off were prevalent in 66% of the 
study population. Most of these participants showed de-
creased cobalamin concentrations ( ! 150 pmol/l, 67%; 
 ! 250 pmol/l, 93%), while folate and pyridoxine status 
were sufﬁ cient. The lack of a signiﬁ cant inﬂ uence of co-
balamin intake on serum concentrations in our study 
population may be due to the low variability of cobalamin 
intake and/or the alleged higher alimentary intake in the 
SV subgroup, which ingested cobalamin in form of en-
riched foods. Intervention studies show that an addition-
al cobalamin intake can sufﬁ ciently increase low serum 
concentrations and decrease elevated homocysteine con-
centrations  [44] . Multiple linear regression analysis 
showed that cobalamin status and duration of adhering 
to the vegan diet were predictive for the homocysteine 
concentrations in our collective. In other studies on veg-
ans more than half of the participants showed homocys-
teine concentrations  1 15   mol/l  [7, 39, 43] , while 35% of 
our study population showed homocysteine concentra-
tions above this value. The prevalence of homocysteine 
concentrations  1 15   mol/l ascended with proceeding du-
ration of vegan diet ( ! 5 years, 25.8%; 5 to  ! 10 years, 
37.8%;  6 10 years, 69.6%; p  ! 0.001). The high preva-
lence of elevated homocysteine in vegans reported here 
and elsewhere may provide one mechanistic explanation 
for the observation that CHD death rates are higher in 
vegans than in lacto-ovo-vegetarians  [18] . In patients 
with CHD or in patients at signiﬁ cant risk for CHD, Lp(a) 
should be measured. Levels  1 10 mg/dl should be treated 
with either high therapeutic doses of niacin or estrogen 
 [10] . In the present study Lp(a) concentrations varied 
greatly. Nearly 46% of the participants had Lp(a) concen-
trations above 10 mg/dl. In general an Lp(a) concentra-
tion of more than 30 mg/dl is accepted as a risk threshold 
for developing cardiovascular disease in apparently 
healthy persons  [45] . A quarter of our study population 
showed these elevated Lp(a) concentrations. Li et al.  [46] 
compared omnivore and vegetarian women regarding 
their lipid proﬁ le and Lp(a) status. In their study cohort, 
Lp(a) concentrations were higher in omnivore women 
than in vegetarian. A signiﬁ cant negative correlation was 
found between Lp(a) concentrations and carbohydrate 
intake. In our study, we were not able to conﬁ rm the lat-
ter ﬁ nding. This may partly be due to the wide variation 
in Lp(a) concentrations in the GVS study population.  
 A limitation of this study is that there was no control 
group. The results were compared between strict vegans 
and moderate vegans that differed only slightly but an in 
important dietary behavior: The inclusion of small 
amounts of foods of animal origin. Due to the lack of an 
omnivore control group it might be possible that the ob-
served effects that were interpreted as a dietary subgroup 
allocation effect might be overestimated.  
 Conclusion 
 Although total and LDL cholesterol concentrations 
were favourable, low HDL cholesterol, elevated homo-
cysteine, and lipoprotein(a) concentrations were unfa-
vourable. Overall, these results conﬁ rm the notion that a 
vegan diet is deﬁ cient in vitamin B 12 , which may have an 
unfavorable effect on CHD risk. 
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